About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Biphasic Insulin Aspart 30 in Type 2 Diabetes Failing OAD Therapy

NCT00598793·27 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Novo Nordisk A/S

Age

18–75

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Insulin naive Type 2 diabetes
Currently treated with OADs alone or combined with other treatment for at least 3 months
BMI below 40 kg/m2 and body weight below 125 kg
HbA1c greater than or equal to 8%

You may not be if

Inability to tolerate metformin or contradictions to its use
Pregnant, breastfeeding or intention of becoming pregnant
Allergy to any of the trial products
Inability or unwillingness to perform SMBG

The record

StatusCompleted

PhasePhase 3

Taking part242

StartedNov 2002

UpdatedJan 9, 2017

Conditions

Diabetes Diabetes Mellitus, Type 2

Where27

Novo Nordisk Investigational Site
Concord, California, United States
Novo Nordisk Investigational Site
Los Angeles, California, United States
Novo Nordisk Investigational Site
Walnut Creek, California, United States

Clareo Health | Biphasic Insulin Aspart 30 in Type 2 Diabetes Failing OAD Therapy